Citadel Advisors
STAB

Citadel Advisors’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Citadel Advisors’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,200
Closed -$2K – 15792
2022
Q3 		$2K Sell
18,200
-1,000
-5% -$211 ﹤0.01% 12435
2022
Q2 		$5K Buy
+19,200
New +$4.96K ﹤0.01% 12688
2014
Q1 		– Sell
-290
Closed -$7K – 8071
2013
Q4 		$7K Sell
290
-70
-19% -$1.9K ﹤0.01% 6784
2013
Q3 		$11K Buy
360
+65
+22% +$2.15K ﹤0.01% 6454
2013
Q2 		$9K Buy
+295
New +$10.2K ﹤0.01% 6270

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's STAB Position: Q2 2022 in Review

Citadel Advisors sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q2 2022, closing a stake of 20,368 shares — an estimated $5.27K sold.

Citadel Advisors first reported a position in STAB in Q2 2013 and held it in 14 quarters. The position peaked at $192K in Q1 2021. 35 funds tracked by Wall St. Rank hold STAB as of Q2 2022.

  • Citadel Advisors reported no remaining Statera Biopharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 20,368 Statera Biopharma, Inc. Common Stock shares in Q2 2022, an estimated $5.27K.
  • Citadel Advisors first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 14 quarters.
  • Citadel Advisors's Statera Biopharma, Inc. Common Stock position peaked at $192K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.